For children with atopic dermatitis (AD), dupilumab treatment restores skin barrier function, according to a study published ...
Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the best growth stocks to buy right now. On March 10, Arcutis ...
Almirall has reported positive top-line results from its phase 3 ADorable-1 trial, which evaluated lebrikizumab in children ...
Pediatric EBGLYSS trial meets endpoints in dermatitis care; Broader immunology portfolio gains attention beyond metabolic therapies; Recent share movement frames respo ...
Pfizer expands oncology and immunology pipeline strength New therapies show progress in clinical development Focus shifts ...
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new ...
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line ...
Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused ...
A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that ...
Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...
Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...
Researchers found that dupilumab improved skin barrier integrity and reduced inflammation in children with atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results